EMA Authorised: Ceprotin (human protein C) — Takeda Manufacturing Austria AG

View source ↗

Summary

The EMA has authorised Ceprotin (human protein C) for therapeutic use in Purpura Fulminans and Protein C Deficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Protein Deficiency
• Purpura Fulminans

Drugs mentioned

• Ceprotin (human protein C)

Snippet

Status: Authorised. Therapeutic area: Purpura Fulminans;Protein C Deficiency. MAH: Takeda Manufacturing Austria AG. Decision date: 03/07/2023